Inotiv, Inc. Bolsters Pathology Services with Acquisition of Histion, LLC
April 25 2022 - 2:00PM
Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or
“Inotiv”), a leading contract research organization
specializing in nonclinical and analytical drug discovery and
development services and research models and related products and
services, today announced the acquisition of Histion, LLC
(“Histion”), effective April 25, 2022. The acquisition is a
strategic element of the Company’s expansion of its specialized
pathology services.
“The acquisition of Histion extends our histology operations
into highly-specialized plastics and medical device pathology,”
said Greg Beattie, Chief Operating Officer, Discovery and
Development Services at Inotiv. “This acquisition will also support
the previously announced expansion of our surgical model and
medical device testing services in Fort Collins, CO, and will
accelerate the development of these services and our future
expansion plans.”
Beattie continued, “We have a valued, longstanding history of
working with Histion, and are confident that the addition of
Histion’s expert team will enable us to better assist our clients
in study design and the effective evaluation of the safety and
efficacy of medical devices across a very broad array of
therapeutic indications.”
Peggy Lalor, President and Founder of Histion, added, “We are
thrilled to be part of Inotiv’s growth. Integrating our pathology
expertise with the comprehensive services at Inotiv will allow us
to provide more complete and flexible solutions to our
clients.”
About Inotiv
Inotiv, Inc. is a leading contract research
organization dedicated to providing nonclinical and analytical drug
discovery and development services and research models and related
products and services. The Company’s products and services focus on
bringing new drugs and medical devices through the discovery and
preclinical phases of development, all while increasing efficiency,
improving data, and reducing the cost of taking new drugs to
market. Inotiv is committed to supporting discovery and development
objectives as well as helping researchers realize the full
potential of their critical R&D projects, all while working
together to build a healthier and safer world. Further information
about Inotiv can be found here: https://www.inotivco.com/.
This release may contain forward-looking
statements that are subject to risks and uncertainties including,
but not limited to, risks and uncertainties related to changes in
the market and demand for our products and services, the
development, marketing and sales of products and services, changes
in technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, the impact of the COVID-19 pandemic
on the economy, demand for our services and products and our
operations, including the measures taken by governmental
authorities to address the pandemic, which may precipitate or
exacerbate other risks and/or uncertainties, expansion and related
efforts, and various other market and operating risks, including
those detailed in the Company's filings with the U.S. Securities
and Exchange Commission.
Company Contact |
Investor Relations |
Inotiv, Inc. |
The Equity Group Inc. |
Beth A. Taylor, Chief Financial Officer |
Kalle Ahl, CFA |
(765) 497-8381 |
(212) 836-9614 |
btaylor@inotivco.com |
kahl@equityny.com |
|
|
|
Devin Sullivan |
|
(212) 836-9608 |
|
dsullivan@equityny.com |
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Inotiv (NASDAQ:NOTV)
Historical Stock Chart
From Apr 2023 to Apr 2024